Arvinas received FDA approval for Veppanu (vepdegestrant) in May 2026, marking the first FDA-approved PROTAC protein degrader for treating ESR1-mutated breast cancer. The company out-licensed global rights to Rigel Pharmaceuticals for $70 million upfront plus up to $320 million in milestones and royalties. Arvinas' diversified pipeline includes candidates for lymphoma, Parkinson's disease, and solid tumors with data expected through 2027.

TG Therapeutics (TGTX) shares have risen 59.9% over six months, driven by robust sales of its marketed drug Briumvi for relapsing multiple sclerosis. Briumvi sales grew 69% to $437.1 million in the first half of 2026, prompting the company to raise its full-year revenue guidance to approximately $950 million. The company is expanding Briumvi's potential through phase II studies for schizophrenia and myasthenia gravis, and developing a subcutaneous formulation expected to deliver data by end of 2026 or Q1 2027.

Mirum Pharmaceuticals announced that its Phase III EXPAND study met the primary endpoint for Livmarli (maralixibat) in treating cholestatic pruritus in patients with ultra-rare cholestatic liver diseases. Livmarli showed a 1.81-point improvement in itch severity versus 0.83 for placebo and achieved a 69% reduction in serum bile acids. The company plans to submit a supplemental new drug application to the FDA in the first half of 2027. Livmarli sales have grown 50.2% year-over-year in the first half of 2026, reaching $242.5 million.

Arvinas presented Phase 1 clinical trial data for ARV-102, a PROTAC LRRK2 degrader, showing dose-dependent improvements in oculomotor function and correlations between LRRK2 reduction and improvements in biomarkers related to endolysosomal function, neuroinflammation, and synaptic integrity in Parkinson's disease patients. The findings support continued clinical evaluation of ARV-102 for neurodegenerative diseases associated with LRRK2 dysregulation.

Arvinas announced the first patient dosing in a Phase 1/2 clinical trial of ARV-6723, an oral PROTAC designed to degrade HPK1 for advanced solid tumors. The drug is Arvinas' first immuno-oncology candidate and the first HPK1 PROTAC degrader to enter clinical trials in the US. Preclinical data showed potent HPK1 degradation, enhanced immune activity, and antitumor effects as monotherapy and in combination with anti-PD-1 therapy, including activity in anti-PD-1-resistant models.

Arvinas announced it has joined The Michael J. Fox Foundation's LRRK2 Investigative Therapeutics Exchange (LITE) program and Parkinson's Precision Medicine Initiative (PPMI) to advance ARV-102, its investigational PROTAC drug targeting LRRK2 for treating Parkinson's disease and progressive supranuclear palsy. The company plans to initiate Phase 1b and potentially Phase 2 registrational trials in PSP patients in the second half of 2026.

The ESR1-mutated metastatic breast cancer market is projected to grow at 9.6% CAGR through 2036, driven by rising prevalence of endocrine-resistant HR-positive/HER2-negative breast cancer and adoption of precision oncology. Novel oral SERDs and targeted agents from major pharmaceutical companies are reshaping the treatment landscape. The market was valued at USD 1.5 billion in 2025, with the US representing the largest market share. Recent FDA approvals include VEPPANU (vepdegestrant), the first PROTAC therapy, while several emerging therapies are in clinical development.

Rigel Pharmaceuticals announced an exclusive global licensing agreement with Arvinas and Pfizer for VEPPANU (vepdegestrant), an oral PROTAC drug for ER+/HER2- ESR1-mutated advanced or metastatic breast cancer. Rigel will contribute up to $40 million toward development over four years and pursue U.S. and global commercialization rights. The drug received FDA approval in May 2026, showing a 43% reduction in disease progression or death risk compared to fulvestrant in the Phase 3 VERITAC-2 trial.

Arvinas, Inc. announced FDA approval of VEPPANU (vepdegestrant), the first-and-only FDA-approved PROTAC protein degrader, for treating estrogen receptor-positive advanced breast cancer with ESR1 mutations. The approval came ahead of the FDA-assigned PDUFA date of June 5, 2026. The company also reported positive Phase 1 data for ARV-102 showing greater than 50% LRRK2 degradation in Parkinson's disease patients.

The FDA approved VEPPANU (vepdegestrant), a first-of-its-kind PROTAC therapy developed by Pfizer and Arvinas for treating advanced breast cancer with ESR1 mutations. The Phase 3 VERITAC-2 trial showed vepdegestrant reduced disease progression risk by 43% compared to fulvestrant, with median PFS of 5 months versus 2.1 months. Guardant Health's Guardant360 CDx was also approved as a companion diagnostic for patient identification.

Arvinas and Pfizer announced FDA approval of VEPPANU (vepdegestrant), the first-ever approved PROTAC protein degrader, for treating ESR1-mutated ER+/HER2- advanced breast cancer. The approval was granted ahead of schedule, based on Phase 3 VERITAC-2 trial data showing vepdegestrant reduced disease progression risk by 43% compared to fulvestrant. The companies plan to select a third-party partner for commercialization.

Arvinas announced it will present Phase 1 clinical trial data for ARV-102, a PROTAC degrader targeting LRRK2, at the AD/PD 2026 conference in Copenhagen on March 18, 2026. The presentation will highlight safety, pharmacokinetic, and pharmacodynamic data from participants with Parkinson's disease. The company plans to initiate a Phase 1b trial in progressive supranuclear palsy patients in the first half of 2026, pending regulatory approval.